RE: Another day closer to phase 1 clinical trial start date24 Oct 2024 10:25
Not convinced this is binary. Maybe it would be if CAR-T were Hemo's only treatment in the pipeline; then perhaps it would be possible that no-one would see it as too niche to be worthy of support. But CAR-T is not Hemo's only product and vital though it will be to its target audience, it has nowhere near as much wide-reaching importance and value as the other discoveries Hemo is developing. Except CAR-T is the gateway treatment whose success (is this right Haywain?) will indicate just how successful the other treatments can be as well. This is just not binary: this is Hemo's beginning.